Delcath Systems, Inc. (DCTH) stock: price, suppliers, customers and institutional ownership
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan hydrochloride for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with hepatic dominant ocular melanoma to investigate objective response rate in metastatic ocular melanoma. The company also provides HEPZATO as a stand-alone medical device for sale under the CHEMOSAT Hepatic Delivery System for Melphalan trade name for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.
the bull case· 2
122
managers reporting a position in regulatory filings
13fJun 30 '26+11.55%
shares held by the largest reporting managers rose over the latest quarter
13fJun 30 '26the bear case· 4
3
of the funds on file reporting a position in the company
n-portas of Jun 30 '260.01%
of the largest fund's assets in the iShares Russell ETF
n-portJun 30 '266 of 8
recent reports with moves below the options implied range
earnings historyimplied vs realized7 of 22
of the largest reporting managers reduced their stake last quarter
13fJun 30 '26Sides and captions by the model; every figure is ours. Built Sep 16 '26 for the Nov 9 '26 report. Not a forecast, not advice.
Of the 6 companies Delcath Systems, Inc. moves with most closely, none share its SEC classification.
Measured against 500 trading days of our own closes. Co-movement, not cause.
SIC 3841, Surgical & Medical Instruments & Apparatus, from each company's own filings. Largest first.
tall tick = annual report · 1 on record
DCTH (Delcath Systems, Inc.) has 0 disclosed suppliers and 1 disclosed customers, strongest disclosure first.
Customers:
Select a tie for its filing sentence; select again to open the company. Nearer the centre, the more the filings disclose. Extended: satellites hang off single companies, not bundled sectors.
121 managers report a position worth $225.5M between them, and 21 of them hold 80% of it.
Delcath Systems, Inc.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Surgical & Medical Instruments & Apparatus
High 16.25 at 10:15 am ET, low 16.06 at 3:15 pm ET.